Search Results - "Tsai, D E"

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder by Reshef, R., Vardhanabhuti, S., Luskin, M. R., Heitjan, D. F., Hadjiliadis, D., Goral, S., Krok, K. L., Goldberg, L. R., Porter, D. L., Stadtmauer, E. A., Tsai, D. E.

“…Reduction of immunosuppression (RI) is commonly used to treat posttransplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients. We…”
Get full text

Treatment of PTLD with Rituximab or Chemotherapy by Elstrom, R.L., Andreadis, C., Aqui, N.A., Ahya, V.N., Bloom, R.D., Brozena, S.C., Olthoff, K.M., Schuster, S.J., Nasta, S.D., Stadtmauer, E.A., Tsai, D.E.

“…Information regarding treatment of post‐transplant lymphoproliferative disease (PTLD) beyond reduction in immunosuppression (RI) is limited. We retrospectively…”
Get full text

Post-transplant lymphoproliferative disorder: a review by LOREN, A. W, PORTER, D. L, STADTMAUER, E. A, TSAI, D. E

“…Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of Epstein-Barr virus-related (EBV) clinical diseases, from a benign…”
Get full text

EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial by Tsai, D. E., Douglas, L., Andreadis, C., Vogl, D. T., Arnoldi, S., Kotloff, R., Svoboda, J., Bloom, R. D., Olthoff, K. M., Brozena, S. C., Schuster, S. J., Stadtmauer, E. A., Robertson, E. S., Wasik, M. A., Ahya, V. N.

“…While EBV PCR is used in the management of PTLD, the optimal primer set, relative importance of intracellular versus free plasma EBV, and the baseline profile…”
Get full text

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma by Olin, R L, Vogl, D T, Porter, D L, Luger, S M, Schuster, S J, Tsai, D E, Siegel, D L, Cook, R J, Mangan, P A, Cunningham, K, Stadtmauer, E A

“…Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional…”
Get full text

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder by Luskin, M. R., Heil, D. S., Tan, K. S., Choi, S., Stadtmauer, E. A., Schuster, S. J., Porter, D. L., Vonderheide, R. H., Bagg, A., Heitjan, D. F., Tsai, D. E., Reshef, R.

“…We examined the associations of Epstein–Barr virus (EBV) status with characteristics and outcomes of posttransplantation lymphoproliferative disorder (PTLD) by…”
Get full text

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease by COHEN, A. D, LUGER, S. M, SICKLES, C, MANGAN, P. A, PORTER, D. L, SCHUSTER, S. J, TSAI, D. E, NASTA, S, GEWIRTZ, A. M, STADTMAUER, E. A

“…Gemtuzumab ozogamicin (GO) (Mylotarg, CMA-676) is a novel chemotherapeutic agent consisting of an anti-CD33 monoclonal antibody linked to calicheamicin, and is…”
Get full text

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS by Jurczak, W., Lamanna, N., Tam, C. S., Kontos, A., Konig, H., Ruppert, A. S., Tsai, D. E.

Get full text

Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders by Tsai, D.E., Reshef, R.

“…This editorial provides commentary on Finalet Ferreiro et al’s study (page 414) demonstrating that Epstein-Barr virus–positive and –negative…”
Get full text

Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignancies by Wang, Y., Coombs, C. C., Shah, N. N., Jurczak, W., Woyach, J., Cheah, C. Y., Patel, K., Maddocks, K., Muehlenbein, C. E., Wang, C., Abhyankar, S., Tsai, D. E., Eyre, T. A.

Get full text

Removal of gadolinium by peritoneal dialysis by Murashima, M, Drott, H R, Carlow, D, Shaw, L M, Milone, M, Bachman, M, Tsai, D E, Yang, S-L, Bloom, R D

“…An association between gadolinium-containing contrast and the development of nephrogenic systemic fibrosis (NSF) has been increasingly recognized. For patients…”
Get more information

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma by ANDREADIS, C, SCHUSTER, S. J, DOWNS, L. H, MANGAN, P. A, CUNNINGHAM, K. A, HUMMEL, K. A, GIMOTTY, P. A, SIEGEL, D. L, GLATSTEIN, E, STADTMAUER, E. A, CHONG, E. A, SVOBODA, J, LUGER, S. M, PORTER, D. L, TSAI, D. E, NASTA, S. D, ELSTROM, R. L, GOLDSTEIN, S. C

“…Although follicular lymphoma (FL) is generally responsive to conventional-dose chemotherapy, improved survival in patients with this disease has been difficult…”
Get full text

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT by Cheah, C. Y., Shah, N. N., Jurczak, W., Zinzani, P. Luigi, Eyre, T. A., Ujjani, C. S., Izutsu, K., Ma, S., Flinn, I., Alencar, A. J., Lewis, D., Patel, K., Maddocks, K., Wang, Y., Munir, T., Zelenetz, A. D., Balbas, M., Tsai, D. E., Wang, C., Wang, M. L.

Get full text

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation by LOREN, A. W, LUGER, S. M, GREEN, J, EMERSON, S. G, PORTER, D. L, STADTMAUER, E. A, TSAI, D. E, SCHUSTER, S, NASTA, S. D, GOLDSTEIN, S. C, PERL, A, ORLOFF, G, OLIVER, J. C

“…Nonmyeloablative stem cell transplantation (NST) harnesses the graft-versus-tumor effect while minimizing regimen-related toxicity, and can result in donor…”
Get full text

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY by Jurczak, W., Shah, N. N., Lamanna, N., Eyre, T. A., Woyach, J., Lech‐Maranda, E., Wierda, W. G., Lewis, D., Thompson, M. C., Wang, D., Yin, M., Balbas, M., Nair, B. C., Zhu, E. Y., Tsai, D. E., Ku, N. C., Coombs, C. C., Mato, A. R.

Get full text

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY by Roeker, L. E., Mato, A. R., Brown, J. R., Coombs, C. C., Shah, N. N., Wierda, W. G., Patel, M. R., Lewis, K. L., Balbas, M., Zhao, J., Ku, N. C., Kherani, J. F., Tsai, D. E., Nair, B., Cheah, C. Y.

Get full text

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation by TSAI, D. E, MOORE, H. C. F, HARDY, C. L, PORTER, D. L, LOH, E. Y, VAUGHN, D. J, LUGER, S, SCHUSTER, S. J, STADTMAUER, E. A

“…We evaluated the response and toxicity of rituximab in the setting of progressive intermediate grade non-Hodgkin's lymphoma (NHL) after autologous peripheral…”
Get full text

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech‐Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C., Lewis, D., Gerson, J. N., Alencar, A. J., Ujjani, C., Flinn, I., Sundaram, S., Ma, S., Jagadeesh, D., Rhodes, J., Taylor, J., Abdel‐Wahab, O., Ghia, P., Schuster, S. J., Wang, D., Nair, B., Zhu, E., Tsai, D. E., Davids, M. S., Brown, J. R., Jurczak, W.

Get full text

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech‐Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., Cheah, C. Y.

Get full text

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS by N Lamanna, CS Tam, W Jurczak, A Kontos, H Konig, AS Ruppert, DE Tsai, AAS Scheliga

“…Objectives: Bruton tyrosine kinase inhibitors (BTKi) are associated with an increased risk of bleeding events. Pirtobrutinib, a non-covalent (reversible) BTKi…”
Get full text